中华皮肤科杂志 ›› 2009, Vol. 42 ›› Issue (9): 635-637.

• 论著 • 上一篇    下一篇

苦参素治疗慢性荨麻疹患者疗效及外周血Foxp3+调节性T细胞的检测

伍斌1,谢红付2,张江林2,等3   

  1. 1. 湘南学院附属医院皮肤科
    2. 湖南 长沙市 中南大学湘雅医院皮肤科
    3. 湖北省中山医院整形美容外科
  • 收稿日期:2008-05-29 修回日期:2008-07-12 出版日期:2009-09-15 发布日期:2012-03-21
  • 通讯作者: 伍斌 E-mail:ruixin598@yahoo.com.cn

Therapeutic efficacy of oxymatrine on chronic urticaria and its contribution to populations of Foxp3+ regulatory T cells in peripheral blood of patients

2, 3, 4   

  • Received:2008-05-29 Revised:2008-07-12 Online:2009-09-15 Published:2012-03-21

PDF (PC)

136

赞

摘要： 目的　探讨苦参素治疗慢性荨麻疹的疗效和免疫学机制。方法　慢性荨麻疹患者69例，分成咪唑斯汀组、联合用药组、苦参素组。3组均连续给药15天，在用药开始后的第7天、14天、21天、28天对瘙痒程度及红斑风团数量进行评估。各组在用药的第0天、14天、28天静脉采血，用抗-Foxp3、抗-CD4、抗-CD25单抗进行免疫荧光标记, 流式细胞仪检测各组Foxp3+CD4+CD25+ T细胞数量。结果　联合用药组及苦参素组荨麻疹疗效明显优于咪唑斯汀组，咪唑斯汀组与联合用药组及苦参素组两两比较差异有统计学意义（t = 49.18，P < 0.01），而联合用药组与苦参素两组比较差异无统计学意义（t = 0.529，P > 0.05）。注射苦参素能显著升高荨麻疹患者外周血中Foxp3+CD4+CD25+ T细胞数量，苦参素各剂量组与正常人对照组及咪唑斯汀组比较差异有统计学意义（t = 24.88，P < 0.01）。结论　苦参素对慢性荨麻疹患者疗效显著。苦参素能显著升高慢性荨麻疹患者外周血中Foxp3+CD4+CD25+ T细胞数量。

关键词: 荨麻疹, 苦参, 治疗, CD4阳性T淋巴细胞

Abstract: Objective To explore the therapeutic effect of oxymatrine on chronic urticaria and its immune mechanism. Methods Totally, 69 patients were randomly and equally divided into 3 groups to receive treatment with oral mizolastine alone （mizolastine group）, oral mizolastine and intramuscular oxymatrine （combination group）, intramuscular oxymatrine alone （oxymatrine group）, respectively. The dose of mizolastine and oxymatrine was 10 mg and 400 mg daily, respectively, and the treatment lasted 15 days. Efficacy was assessed according to pruritus intensity and number of erythema and wheals on day 7, 14, and 28 after the beginning of treatment. Venous blood was obtained from patients at the baseline, on day 14, 28 after the initiating of treatment and subjected to the detection of CD4+Foxp3+ regulatory T cell populations via three-color fluorescence flow cytometric analysis. Results The efficacy in combination and oxymatrine groups were significantly higher than that in mizolastine group （t = 49.18, P < 0.01）, while there was no statistical difference between the combination group and oxymatrine group （t = 0.529, P > 0.05）. The proportion of Foxp3+CD4+CD25+ regulatory T cells in peripheral blood was significantly increased in patients treated with oxymatrine, compared with normal human controls and patients treated with mizolastine （all P < 0.05）. Conclusions Oxymatrine has a marked effect on the treatment of chronic urticaria, likely by increasing the proportion of Foxp3+CD4+CD25+ regulatory T cells in peripheral blood of patients.